Cowen Starts Unum Therapeutics (UMRX) at Market Perform

Go back to Cowen Starts Unum Therapeutics (UMRX) at Market Perform

Wedbush Starts Unum Therapeutics (UMRX) at Outperform

April 23, 2018 6:43 AM EDT

Wedbush initiates coverage on Unum Therapeutics (NASDAQ: UMRX) with a Outperform rating and a price target of $18.00.

Analyst David Nierengarten comments "UMRX shares are undervalued given the universal approach of their proprietary Antibody-Coupled T-Cell Receptor (ACTR) platform, an engineered cell construct with... More

SunTrust Robinson Humphrey Starts Unum Therapeutics (UMRX) at Buy

April 23, 2018 6:22 AM EDT

SunTrust Robinson Humphrey initiates coverage on Unum Therapeutics (NASDAQ: UMRX) with a Buy rating and a price target of $21.00.

For an analyst ratings summary and ratings history on Unum Therapeutics click here. For more ratings news on Unum Therapeutics click here.

Shares of Unum Therapeutics closed at $11.98 Friday.

... More

Morgan Stanley Starts Unum Therapeutics (UMRX) at Overweight

April 23, 2018 5:35 AM EDT

Morgan Stanley initiates coverage on Unum Therapeutics (NASDAQ: UMRX) with a Overweight rating and a price target of $20.00.

For an analyst ratings summary and ratings history on Unum Therapeutics click here. For more ratings news on Unum Therapeutics click here.

Shares of Unum Therapeutics closed at $11.98 Friday.

... More